Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Oseltamivir (OA), an ethyl ester prodrug of oseltamivir carboxylate (OC), is clinically used as a potent and selective inhibitor of neuraminidase. Chinese medicines have been advocated to combine with conventional drug for avian influenza. The current study aims to investigate the potential pharmacokinetic and pharmacodynamic interactions of a Chinese medicine formula, namely, Yin Qiao San and Sang Ju Yin (CMF1), commonly used for anti-influenza in combination with OA in both rat and human, and to reveal the underlined mechanisms. It was found that although C-max, AUC and urinary recovery of OC, as well as metabolic ratio (AUC(OC)/AUC(OA)), were significantly decreased in a dose-dependent manner following combination use of CMF1 and OA in rat studies (P < 0.01), such coadministration in 14 healthy volunteers only resulted in a trend of minor decrease in the related parameters. Further mechanistic studies found that although CMF1 could reduce absorption and metabolism of OA, it appears to enhance viral inhibition of OA (P < 0.01). In summary, although there was potential interaction between OA and CMF1 found in rat studies, its clinical impact was expected to be minimal. The coadministration of OA and CMF1 at the clinical recommended dosages is, therefore, considered to be safe.
著者Chang Q, Wo S, Ngai KLK, Wang XA, Fok B, Ngan TM, Wong VT, Chan TYK, Lee VHL, Tomlinson B, Chan PKS, Chow MSS, Zuo Z
期刊名稱Evidence-Based Complementary and Alternative Medicine
出版年份2014
月份1
日期1
出版社Hindawi Publishing Corporation / Oxford University Press (OUP): Policy B
國際標準期刊號1741-427X
電子國際標準期刊號1741-4288
語言英式英語
Web of Science 學科類別Integrative & Complementary Medicine; INTEGRATIVE & COMPLEMENTARY MEDICINE

上次更新時間 2021-22-01 於 00:24